Editorial Epidemiology/Public Health
Does tranexamic acid reduce in-hospital mortality in patients with heart failure? A pilot feasibility study

Does tranexamic acid reduce in-hospital mortality in patients with heart failure? A pilot feasibility study

Authors

Lucas Tanaka

Lucas Tanaka

King Fahad Medical City, Mayotte

Corresponding
Malik Rossi

Malik Rossi

St Thomas' Hospital, Ireland

Published

February 17, 2025

Paper ID

PAP-000164

Status

Published

DOI

10.65712/tmj.test000422

Does tranexamic acid reduce in-hospital mortality in patients with heart failure? A pilot feasibility study

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around tranexamic acid varies widely between centres. Methods: Analyses were adjusted for age, sex and baseline severity. Results: The adjusted odds ratio was 0.44 (95% CI 0.44 to 0.67). in-hospital mortality occurred in 17% of the intervention group versus 36% of controls. Conclusion: Residual confounding cannot be excluded.

References

1. Farouk I, Herrera X, et al. Early mobilisation and medication adherence. BMC Med. 2022;10(2):284-1544.

2. Ibrahim K, Rahman Z, et al. Home-based cardiac rehabilitation and falls. JAMA. 2011;94(8):514-1678.

3. Rahman C, Tanaka T, et al. Continuous glucose monitoring and acute kidney injury. Pediatrics. 2017;314(10):733-1598.

4. Okafor T, Zhang R, et al. Continuous glucose monitoring and medication adherence. Diabetes Care. 2018;228(10):483-1645.

5. Costa N, Costa X, et al. Low-dose aspirin and in-hospital mortality. Lancet. 2012;383(8):763-1298.

6. Dubois T, Rossi U, et al. Continuous glucose monitoring and time to diagnosis. Diabetes Care. 2019;68(9):364-1218.

7. Silva X, Yilmaz A, et al. An antibiotic stewardship programme and surgical site infection. Lancet. 2024;326(7):436-1111.

8. Okafor K, Zhang X, et al. Vitamin D supplementation and glycaemic control. N Engl J Med. 2016;110(2):327-1581.

Introduction

Practice around tranexamic acid varies widely between centres.

Guidelines make only a weak recommendation on tranexamic acid. Earlier studies of tranexamic acid were small or single-centre. Practice around tranexamic acid varies widely between centres.

Materials and Methods

We conducted a pilot feasibility study across 10 centres between 2017 and 2021. Eligible participants were patients with heart failure.

Missing data were handled with multiple imputation. Eligible participants were patients with heart failure.

Results

Serious adverse events were rare and similar between groups. 3517 participants were included (median age 39 years). in-hospital mortality occurred in 17% of the intervention group versus 35% of controls. in-hospital mortality occurred in 19% of the intervention group versus 29% of controls.

Effects were consistent across prespecified subgroups. 1067 participants were included (median age 31 years).

Serious adverse events were rare and similar between groups. 522 participants were included (median age 28 years). in-hospital mortality occurred in 11% of the intervention group versus 13% of controls.

GroupnEventsRate %OR95% CI
Control6735825.30.770.24–1.15
Intervention7328023.30.840.52–1.25
Control616916.50.640.47–1.1
TABLE 1: Primary outcome by group
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Distribution of in-hospital mortality
Shown for patients with heart failure; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Distribution of in-hospital mortality
Shown for patients with heart failure; error bars are 95% confidence intervals.

in-hospital mortality occurred in 4% of the intervention group versus 38% of controls. Serious adverse events were rare and similar between groups.

Discussion

Future work should test tranexamic acid in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.

Future work should test tranexamic acid in a pragmatic multicentre trial. Residual confounding cannot be excluded.

These findings suggest that tranexamic acid is associated with better in-hospital mortality in patients with heart failure. Implementation will depend on staffing, cost and local protocols. Future work should test tranexamic acid in a pragmatic multicentre trial.

Future work should test tranexamic acid in a pragmatic multicentre trial. These findings suggest that tranexamic acid is associated with better in-hospital mortality in patients with heart failure.

Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded.

Conclusions

Tranexamic acid may be offered for patients with heart failure to improve in-hospital mortality.

Appendices

The statistical analysis plan is in the online supplement.